<!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Pharma Daily Brief | PiercePharma 朝刊</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Noto+Sans+JP:wght@400;500;600;700&family=IBM+Plex+Sans:wght@400;500;600&display=swap" rel="stylesheet">
  <style>
    :root {
      --bg-main: #0f1419;
      --bg-card: #1a2332;
      --bg-card-hover: #232f42;
      --text-primary: #e8edf4;
      --text-secondary: #94a3b8;
      --text-muted: #64748b;
      --accent-pipeline: #38bdf8;
      --accent-regulatory: #fb923c;
      --accent-deals: #4ade80;
      --accent-earnings: #a78bfa;
      --border: #2d3a4f;
      --link: #7dd3fc;
      --link-hover: #bae6fd;
    }
    * { box-sizing: border-box; margin: 0; padding: 0; }
    body { font-family: 'IBM Plex Sans', 'Noto Sans JP', sans-serif; background: var(--bg-main); color: var(--text-primary); line-height: 1.6; min-height: 100vh; padding: 24px 16px; }
    .container { max-width: 720px; margin: 0 auto; }
    .header { margin-bottom: 32px; padding-bottom: 20px; border-bottom: 1px solid var(--border); }
    .header h1 { font-size: 1.5rem; font-weight: 700; letter-spacing: -0.02em; }
    .header .date { font-size: 0.875rem; color: var(--text-muted); margin-top: 4px; font-weight: 500; }
    .header .subtitle { font-size: 0.8125rem; color: var(--text-secondary); margin-top: 8px; }
    .header .scope { font-size: 0.75rem; color: var(--text-muted); margin-top: 12px; padding: 10px 12px; background: var(--bg-card); border-radius: 6px; border: 1px solid var(--border); line-height: 1.5; }
    .header .scope strong { color: var(--text-secondary); }
    .category-section { margin-bottom: 28px; }
    .category-header { display: flex; align-items: center; gap: 8px; margin-bottom: 12px; font-size: 0.8125rem; font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; }
    .category-header .badge { width: 8px; height: 8px; border-radius: 50%; }
    .category-pipeline .badge { background: var(--accent-pipeline); } .category-pipeline .category-header { color: var(--accent-pipeline); }
    .category-regulatory .badge { background: var(--accent-regulatory); } .category-regulatory .category-header { color: var(--accent-regulatory); }
    .category-deals .badge { background: var(--accent-deals); } .category-deals .category-header { color: var(--accent-deals); }
    .category-earnings .badge { background: var(--accent-earnings); } .category-earnings .category-header { color: var(--accent-earnings); }
    .article-card { background: var(--bg-card); border: 1px solid var(--border); border-left: 3px solid; border-radius: 8px; padding: 16px; margin-bottom: 12px; transition: background 0.2s; }
    .article-card:hover { background: var(--bg-card-hover); }
    .article-card.pipeline { border-left-color: var(--accent-pipeline); }
    .article-card.regulatory { border-left-color: var(--accent-regulatory); }
    .article-card.deals { border-left-color: var(--accent-deals); }
    .article-card.earnings { border-left-color: var(--accent-earnings); }
    .article-card .title { font-size: 1rem; font-weight: 600; margin-bottom: 8px; line-height: 1.4; }
    .article-card .title a { color: var(--text-primary); text-decoration: none; transition: color 0.2s; }
    .article-card .title a:hover { color: var(--link-hover); }
    .article-card .summary { font-size: 0.875rem; color: var(--text-secondary); margin-bottom: 10px; line-height: 1.5; }
    .article-card .meta { display: flex; flex-wrap: wrap; gap: 12px; font-size: 0.75rem; color: var(--text-muted); }
    .article-card .meta span { display: inline-flex; align-items: center; gap: 4px; }
    .article-card .link-wrap { margin-top: 10px; }
    .article-card .link-wrap a { font-size: 0.8125rem; color: var(--link); text-decoration: none; transition: color 0.2s; }
    .article-card .link-wrap a:hover { color: var(--link-hover); text-decoration: underline; }
    .article-card .link-wrap a::after { content: '→'; }
    .importance { display: inline-flex; gap: 2px; }
    .importance .star { color: var(--accent-regulatory); font-size: 0.7rem; }
    .importance .star.empty { color: var(--text-muted); opacity: 0.5; }
    .article-card .meta .region { font-size: 0.7rem; padding: 2px 6px; border-radius: 4px; font-weight: 500; }
    .region-us { background: rgba(56,189,248,0.2); color: var(--accent-pipeline); }
    .region-europe { background: rgba(251,146,60,0.2); color: var(--accent-regulatory); }
    .region-china { background: rgba(74,222,128,0.2); color: var(--accent-deals); }
    @media (max-width: 480px) { body { padding: 16px 12px; } .header h1 { font-size: 1.25rem; } .article-card { padding: 14px; } }
  </style>
</head>
<body>
  <div class="container">
    <header class="header">
      <h1>Pharma Daily Brief</h1>
      <div class="date">2026年02月28日（土）</div>
      <div class="subtitle">パイプライン・規制・M&A・決算｜医薬・バイオ業界の重要ニュース（毎朝更新）</div>
      <div class="scope">
        <strong>対象地域：</strong>約9割は米国。欧州はノボノルディスク、ブリストルマイヤーズスクイーブ、サノフィ、ロッシュ、バイエルなど大手の重要ニュースを追加。中国は個別企業より<strong>医薬品規制当局の動向</strong>（変化が大きい場合）を掲載。
      </div>
    </header>


    <section class="category-section category-pipeline">
      <h2 class="category-header">
        <span class="badge"></span>
        Pipeline
      </h2>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/webinars/partnering-to-advance-drug-delivery-innovation" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/webinars/partnering-to-advance-drug-delivery-innovation&quot; hreflang=&quot;en&quot;&gt;Partnering to Advance Drug Delivery Innovation&lt;/a&gt;</a></h3>
        <p class="summary">In this webinar, which is a rebroadcast from the 2025 PODD Conference, business development and technology assessment professionals actively involved in the scouting and evaluating of novel delivery t…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/webinars/partnering-to-advance-drug-delivery-innovation" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/webinars/how-pharma-is-expanding-its-global-footprint-to-advance-clinical-research" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/webinars/how-pharma-is-expanding-its-global-footprint-to-advance-clinical-research&quot; hreflang=&quot;en&quot;&gt;How Pharma is Expanding its Global Footprint to Advance Clinical Research&lt;/a&gt;</a></h3>
        <p class="summary">This webinar addresses how pharmaceutical organizations are expanding their clinical trial operations globally to support evolving portfolios and react to geopolitics.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/webinars/how-pharma-is-expanding-its-global-footprint-to-advance-clinical-research" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/new-standard-merck-welireg-combos-deliver-one-two-punch-kidney-cancer" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/new-standard-merck-welireg-combos-deliver-one-two-punch-kidney-cancer&quot; hreflang=&quot;en&quot;&gt;A new standard? Merck&#x27;s Welireg combos deliver 1-2 punch to kidney cancer&lt;/a&gt;</a></h3>
        <p class="summary">The treatment landscape for clear cell renal cell carcinoma could be due for a shake-up following dual breakthroughs from Merck’s Litespark clinical trial program for Welireg. But one critical factor …</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/new-standard-merck-welireg-combos-deliver-one-two-punch-kidney-cancer" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/manufacturing/merck-lay-nearly-150-staffers-research-triangle-area-vaccine-plant" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/manufacturing/merck-lay-nearly-150-staffers-research-triangle-area-vaccine-plant&quot; hreflang=&quot;en&quot;&gt;Merck to wind down Gardasil production at N.C. plant, lay off 150-plus&lt;/a&gt;</a></h3>
        <p class="summary">In a Worker Adjustment and Retraining Notification Act alert filed this week, Merck revealed that it is laying off 147 staffers at a vaccine manufacturing plant in Durham. The cuts are a result of Mer…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/manufacturing/merck-lay-nearly-150-staffers-research-triangle-area-vaccine-plant" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/biotech/lilly-debuts-nvidia-supercomputer-fanfare-and-focus-escaping-traditional-pharma-lifecycle" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/biotech/lilly-debuts-nvidia-supercomputer-fanfare-and-focus-escaping-traditional-pharma-lifecycle&quot; hreflang=&quot;en&quot;&gt;Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle&lt;/a&gt;</a></h3>
        <p class="summary">On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. The first pharma to reach a $1 trillion valuation teaming up with a tech firm that has ridden the AI wave to a reco…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/biotech/lilly-debuts-nvidia-supercomputer-fanfare-and-focus-escaping-traditional-pharma-lifecycle" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/marketing/sanofi-genentech-kedrion-back-star-studded-bleeding-disorder-awareness-campaign" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/marketing/sanofi-genentech-kedrion-back-star-studded-bleeding-disorder-awareness-campaign&quot; hreflang=&quot;en&quot;&gt;Sanofi, Genentech, Kedrion back star-studded bleeding disorder awareness campaign&lt;/a&gt;</a></h3>
        <p class="summary">A handful of pharmas and celebrities are joining forces with the National Bleeding Disorders Foundation for a long-lasting awareness push.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/marketing/sanofi-genentech-kedrion-back-star-studded-bleeding-disorder-awareness-campaign" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/after-chmp-nod-moderna-ceo-applauds-eus-rigorous-scientific-review" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/after-chmp-nod-moderna-ceo-applauds-eus-rigorous-scientific-review&quot; hreflang=&quot;en&quot;&gt;After CHMP nod, Moderna CEO applauds EU&#x27;s &#x27;rigorous scientific review&#x27;&lt;/a&gt;</a></h3>
        <p class="summary">While the FDA has flip-flopped on whether to review Moderna’s combination influenza/COVID-19 vaccine, it’s full speed ahead for the mRNA shot in Europe, with a positive recommendation from the CHMP.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/after-chmp-nod-moderna-ceo-applauds-eus-rigorous-scientific-review" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/ucbs-fast-growing-powerhouse-bimzelx-crosses-blockbuster-sales-threshold-back-heavy-hitting" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/ucbs-fast-growing-powerhouse-bimzelx-crosses-blockbuster-sales-threshold-back-heavy-hitting&quot; hreflang=&quot;en&quot;&gt;UCB&#x27;s fast-growing Bimzelx leaps across blockbuster sales threshold as HS momentum builds&lt;/a&gt;</a></h3>
        <p class="summary">Two years and five indications later, UCB&#x27;s immunology blockbuster Bimzelx is halfway to the company&#x27;s initial goal of at least 4 billion euros ($4.4 billion) in peak sales.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/ucbs-fast-growing-powerhouse-bimzelx-crosses-blockbuster-sales-threshold-back-heavy-hitting" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/scotus-weighs-skinny-labels-top-us-lawyer-calls-toss-amarin-case-over-hikmas-vascepa-generic" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/scotus-weighs-skinny-labels-top-us-lawyer-calls-toss-amarin-case-over-hikmas-vascepa-generic&quot; hreflang=&quot;en&quot;&gt;As SCOTUS takes on &#x27;skinny label&#x27; review, top US lawyer sides with generics maker&lt;/a&gt;</a></h3>
        <p class="summary">As one long-running feud over the controversial generic drug carve-out known as “skinny” labeling comes to a close, the U.S.’ top lawyer is urging the Supreme Court to reverse a recent decision on ano…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/scotus-weighs-skinny-labels-top-us-lawyer-calls-toss-amarin-case-over-hikmas-vascepa-generic" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/padcev-keytruda-redefine-mibc-care-survival-win-amid-shifting-landscape" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/padcev-keytruda-redefine-mibc-care-survival-win-amid-shifting-landscape&quot; hreflang=&quot;en&quot;&gt;Padcev-Keytruda combo aces another bladder cancer trial as MIBC landscape becomes more complex&lt;/a&gt;</a></h3>
        <p class="summary">The combination of Padcev and Keytruda has once again delivered strong results, this time significantly improving overall survival for patients with cisplatin-eligible muscle-invasive bladder cancer. …</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/padcev-keytruda-redefine-mibc-care-survival-win-amid-shifting-landscape" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>
    </section>

    <footer style="margin-top: 40px; padding-top: 20px; border-top: 1px solid var(--border); font-size: 0.75rem; color: var(--text-muted);">
      Pharma Daily Brief — PiercePharma 朝刊 | 米国中心・欧州大手・中国規制を含む医薬・バイオ業界の重要ニュース
    </footer>
  </div>
</body>
</html>